Insulin Degludec Injection, Solution
Product Images NDC 50090-7176

Product Visual Gallery

This gallery contains 61 technical images submitted to the FDA as part of the official labeling for Insulin Degludec (NDC 50090-7176). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Structural Formula Of Tresiba (Image 01)

Chemical structure diagram of insulin degludec showing its amino acid sequence and specific molecular components, including peptide chains and side groups.*

FDA Label Image

Figure 2: Mean Gir Profile For 0.4 U/kg Dose Of Tresiba (steady State) In Patients With Type 1 Diabetes Mellitus (Image 02)

A line graph illustrating the glucose infusion rate (GIR) over time since injection (in hours) for insulin degludec at a dose of 0.4 U/kg. The x-axis represents time up to 42 hours, and the shaded area marks the 24-hour interval.*

FDA Label Image

Vial Ifu-1 (Image 03)

An illustration of a vial labeled with a tamper-resistant cap that includes a rubber stopper under the cap. The vial is depicted simply to show the typical design feature for a vial used for injection solutions.*

FDA Label Image

Vial Ifu-2 (Image 04)

A simple line-drawn illustration showing a hand holding a small vial or bottle, likely representing the handling of an insulin degludec injection solution vial for subcutaneous administration.*

FDA Label Image

Vial Ifu-figure A,b (Image 05)

A two-panel instructional illustration showing a hand holding an insulin pen and preparing it for use. The first panel depicts inserting or attaching a component to the pen, and the second panel shows the final adjustment step before injection. The illustration is related to insulin degludec injection preparation and administration.*

FDA Label Image

Vial Ifu-figure C (Image 06)

An instructional diagram showing hands preparing an insulin injection. One hand holds an insulin pen or syringe upright with a small cap or needle cover, and an arrow points downward to indicate the removal of the cover or cap in a stepwise process detailed in the inset image.*

FDA Label Image

Vial Ifu-figure D (Image 07)

An instructional illustration showing a hand holding a vial and a syringe. The image depicts the process of drawing medication from the vial into the syringe, indicated by an arrow pointing downward from the vial to the syringe needle.*

FDA Label Image

Vial Ifu-figure E (Image 08)

An instructional illustration showing a hand holding a syringe and another hand holding a vial, with an arrow indicating the action of drawing liquid from the vial into the syringe. This diagram likely demonstrates proper technique for preparing an insulin degludec injection solution by subcutaneous route.*

FDA Label Image

Vial Ifu-figure F (Image 09)

An instructional illustration showing a hand holding a syringe above a vial or injection site with a downward arrow, indicating the action of drawing insulin degludec solution for subcutaneous injection.*

FDA Label Image

Vial Ifu-figure G (Image 10)

An instructional illustration showing a hand holding an insulin vial upside down with a needle attached, indicating the process of drawing insulin from the vial into a syringe. Another hand is positioned nearby, suggesting preparation for injection or handling the syringe.*

FDA Label Image

Vial Ifu-figure H (Image 11)

An instructional illustration showing a hand holding a vial or cartridge with an arrow indicating to pull or lift it upward. An inset image shows a close-up of the vial/cartridge with measurement markings and a capped top. The diagram suggests a step in preparing or using an injection solution, likely related to insulin degludec administration.*

FDA Label Image

Vial Ifu-figure I (Image 12)

An instructional illustration showing a hand holding an injection pen with the other hand preparing to use the injection. A downward arrow indicates the direction of pressing or administering the injection, suggesting a step in the subcutaneous injection process for Insulin Degludec 100 U/mL.*

FDA Label Image

Vial Ifu-figure J (Image 13)

An instructional illustration showing two front and back views of a human body with highlighted areas indicating common injection sites for subcutaneous administration of insulin degludec. The front view highlights the abdomen and thighs, while the back view highlights the upper arms and buttocks.*

FDA Label Image

Vial Ifu-figure K (Image 14)

An instructional illustration showing a hand holding an injection pen poised to inject subcutaneously into a forearm. The image depicts the process of administering insulin degludec injection solution by subcutaneous injection.*

FDA Label Image

Vial Ifu-figure L (Image 15)

An instructional illustration showing the use of a syringe for subcutaneous injection. It depicts a hand holding the syringe with the needle pointed downward toward the skin on the forearm, with an arrow indicating the direction of injection.*

FDA Label Image

Figure A: Novofine Needle Components (Image 16)

An instructional illustration showing the components of a NovoFine needle. The parts are labeled as outer needle cap, inner needle cap, needle, and paper tab arranged from left to right.*

FDA Label Image

Figure A: Novotwist Needle Components (Image 17)

An instructional illustration labeled NovoTwist showing the components of an insulin injection needle assembly, including the outer needle cap, inner needle cap, needle, and paper tab, arranged from left to right.*

FDA Label Image

Figure A (Image 18)

An illustrated diagram of an Insulin Degludec Injection FlexTouch pen showing labeled components including the pen cap, insulin scale, insulin window, dose counter, dose pointer, dose selector, and dose button. The pen body displays the product name Insulin Degludec Injection FlexTouch with a note indicating it is for single patient use only.*

FDA Label Image

100 U/ml Ifu (Figure B)

An instructional diagram showing a close-up of two hands preparing a subcutaneous injection device by twisting or removing a segment, likely the cap of an insulin injection pen, as part of the administration process for insulin degludec injection solution 100 U/mL.*

FDA Label Image

100 U/ml Ifu (Figure C)

An illustration showing the preparation of an insulin degludec injection, specifically a hand holding a pen injector with a needle attached, demonstrating how to hold the device prior to subcutaneous injection.*

FDA Label Image

100 U/ml Ifu (Figure D)

Instructional illustration showing the proper technique for attaching NovoFine and NovoTwist needles to an injection device. The image highlights aligning and pushing the needle onto the device with directional arrows indicating the movement.*

FDA Label Image

100 U/ml Ifu (Figure E)

Instructional illustration showing the use of NovoFine and NovoTwist devices. The image depicts hands attaching a needle to an injection pen by twisting and pushing motions, demonstrating steps for preparing subcutaneous injection devices.*

FDA Label Image

100 U/ml Ifu (Figure F)

An instructional illustration labeled Figure F showing how to connect a NovoFine needle to a NovoTwist insulin syringe or pen injector. The image uses arrows to indicate the twisting motion required to attach the needle securely before use.*

FDA Label Image

100 U/ml Ifu (Figure G)

An instructional illustration showing the assembly or use of a pen injector device with labels NovoFine and NovoTwist. The diagram depicts inserting or connecting a needle to the pen injector, indicated by arrows guiding the steps.*

FDA Label Image

100 U/ml Ifu (Figure H)

An instructional illustration showing a close-up of hands adjusting a dial on an insulin injection pen. The dial indicates 2 units selected for injection. This visual guides users in setting the correct insulin dose on the device.*

FDA Label Image

100 U/ml Ifu (Figure I)

An illustration showing a hand holding an insulin pen injector, preparing to administer a subcutaneous injection of insulin degludec 100 U/mL. The image demonstrates the correct grip and positioning for injection using the pen device.*

FDA Label Image

100 U/ml Ifu (Figure J)

An instructional diagram showing a hand holding an insulin degludec injection pen, demonstrating the step of removing the protective cap by pulling it upward. The pen is blue and yellow with a clear dosing window, emphasizing proper handling for subcutaneous injection.*

FDA Label Image

100 U/ml Ifu (Figure K)

An instructional illustration showing dosage selection on an insulin injection pen for Insulin Degludec 100 U/mL. It depicts a hand adjusting the dose dial, with examples of dose windows displaying 5 units and 24 units selected, indicating how to set the desired injection amount.*

FDA Label Image

100 U/ml Ifu (Figure L)

An illustration of a syringe pen showing an approximate scale for insulin dosage, indicating a level around 200 units left. The pen is light yellow with a transparent section showing the insulin solution and dosage markings on the side.*

FDA Label Image

100 U/ml Ifu (Figure M)

An instructional anatomical illustration showing front and back views of a human body with highlighted areas suitable for subcutaneous injection, including the abdomen, upper arms, and thighs.*

FDA Label Image

100 U/ml Ifu (Figure N)

An instructional illustration showing a hand holding a yellow insulin pen with a blue dial, pointing downward. A large blue arrow indicates the direction to press or apply force downwards, likely demonstrating how to operate or prepare the injection pen for subcutaneous administration.*

FDA Label Image

100 U/ml Ifu (Figure O)

An instructional illustration demonstrating the correct technique for injecting. It shows a hand holding a syringe with an arrow indicating downward movement, aiming the needle into a forearm injection site. An inset image displays the syringe dial set to zero.*

FDA Label Image

100 U/ml Ifu (Figure P)

An instructional illustration showing a hand holding a vial upside down with a speech bubble indicating to count slowly 1-2-3-4-5-6. This likely demonstrates a step for preparing or handling an injection solution such as insulin degludec.*

FDA Label Image

100 U/ml Ifu (Figure Q)

An instructional diagram illustrating a step involving a prefilled injection pen, likely demonstrating how to operate or prepare it for use. The pen is positioned vertically with an upward-pointing arrow indicating a pulling or lifting motion above the pen.*

FDA Label Image

100 U/ml Ifu (Figure R)

Illustration showing step-by-step instructions for using an injection device, including removing a NovoFine needle and NovoTwist needle from their packaging in preparation for an insulin injection.*

FDA Label Image

100 U/ml Ifu (Figure S)

An instructional diagram showing the assembly of a cap onto the end of a syringe or pen device, with arrows indicating the direction to push the cap onto the device.*

FDA Label Image

100 U/ml Ifu (Figure T)

An instructional illustration showing fingers removing or peeling a protective cap or seal from a cylindrical injection device or pen, demonstrated by an arrow indicating the direction of removal.*

FDA Label Image

U200 Figure A (Image 38)

Illustration of an Insulin Degludec injection pen showing its components labeled: pen cap, insulin scale, insulin window, dose counter, dose pointer, dose selector, and dose button. The label on the pen indicates it is a 200 U/3 mL FlexTouch device for single patient use.*

FDA Label Image

Figure A: Novofine Needle Components (Image 40)

An instructional diagram showing the components of a NovoFine needle, labeled as outer needle cap, inner needle cap, needle, and paper tab, arranged from left to right. The parts are presented visually for identification or assembly guidance.*

FDA Label Image

Figure A: Novotwist Needle Components (Image 41)

An instructional illustration labeled NovoTwist shows four components related to an injection needle: Outer needle cap, Inner needle cap, Needle, and Paper tab. The diagram visually differentiates each part sequentially from left to right.*

FDA Label Image

200 U/ml Ifu Figure B (Image 43)

An instructional illustration showing a close-up of two hands handling an injection device. One hand holds the device steady while the other hand removes or places a detachable cap or cover, indicated by an arrow pointing to the right. The image likely demonstrates a step in preparing an injection, relevant to subcutaneous administration.*

FDA Label Image

200 U/ml Ifu Figure C (Image 44)

An instructional illustration labeled as Figure C, showing the close-up view of an insulin injection pen with a clear window displaying the dosage scale on the device. The image likely relates to the proper use or dose setting of the pen for subcutaneous administration of insulin degludec 100 U/mL by A-S Medication Solutions.*

FDA Label Image

200 U/ml Ifu Figure D (Image 45)

Illustration showing how to remove the cap from a NovoFine or NovoTwist needle by twisting and pulling it off with the fingers. This instructional figure depicts the proper method for detaching the needle cap before insulin injection.*

FDA Label Image

200 U/ml Ifu Figure E (Image 46)

An instructional illustration showing two steps for assembling or using a NovoFine and NovoTwist device. The image demonstrates how to attach or twist a needle cap onto the insulin pen device, indicated by arrows guiding the motion. The illustration is labeled as Figure E.*

FDA Label Image

200 U/ml Ifu Figure F (Image 47)

Instructional diagram showing the connection of a NovoFine needle to a NovoTwist injection pen. The illustration uses arrows to indicate the steps for attaching the needle securely to the pen device for insulin injection.*

FDA Label Image

200 U/ml Ifu Figure G (Image 48)

An instructional illustration showing two steps for using an insulin injection device. The first panel demonstrates attaching a needle to the device by aligning and securing it. The second panel shows removing the needle cap prior to injection.*

FDA Label Image

200 U/ml Ifu Figure H (Image 49)

An instructional illustration showing the dosage dial of an insulin injection pen set to 2 units, with an arrow indicating the turning motion to select the dose. The image demonstrates how a user adjusts the insulin dose using the dial mechanism.*

FDA Label Image

Figure 3 (Image 52)

A line graph showing cumulative percentage of subjects with an event over time (in months) for Insulin Degludec (IDeg) and Insulin Glargine (IGlar). The x-axis represents time to first event from 0 to 30 months, and the y-axis shows percentage of subjects up to 10%. Two lines compare IDeg and IGlar, with a hazard ratio and 95% confidence interval noted on the graph.*

FDA Label Image

200 U/ml Ifu Figure I (Image 53)

An instructional illustration showing a hand holding an injection pen device with an insulin cartridge inside. The image indicates pressing or activating the injection pen, likely part of a step-by-step guide for using or priming the insulin injection pen for subcutaneous administration.*

FDA Label Image

200 U/ml Ifu Figure J (Image 54)

An instructional illustration showing a hand holding a pen-like injector device for Insulin Degludec injection, solution 100 U/mL. The image highlights a rotation or removal motion indicated by an upward arrow, presumably demonstrating how to manipulate a component of the injector before use.*

FDA Label Image

200 U/ml Ifu Figure K (Image 55)

Illustration showing a close-up of a hand adjusting the dose selector on an insulin pen injector. The display window indicates dosage selections of 6 units and 24 units, with arrows demonstrating how to rotate the dial to choose the desired unit dose for injection.*

FDA Label Image

200 U/ml Ifu Figure L (Image 56)

An illustration showing a close-up of a dose measurement on a pen injector for insulin degludec, indicating approximate units on the dose window. The image highlights a dose approximately 400 units left in the pen. It is a visual guide related to subcutaneous injection dosing for insulin degludec.*

FDA Label Image

200 U/ml Ifu Figure M (Image 57)

An instructional diagram showing front and back outlines of a human body highlighting recommended subcutaneous injection sites on the abdomen, upper arms, front and outer thighs, and upper buttocks or hip areas.*

FDA Label Image

200 U/ml Ifu Figure N (Image 58)

An instructional diagram showing a hand holding an insulin pen vertically downward with an arrow indicating to point the pen straight down, labeled as Figure N. This is likely demonstrating part of the usage or preparation steps for an insulin injection device.*

FDA Label Image

200 U/ml Ifu Figure O (Image 59)

An instructional illustration showing a hand holding an insulin degludec injection pen with an arrow pointing downwards, indicating an action related to dose delivery or preparation. A separate inset displays a dial icon with a zero, likely referencing dose adjustment or reset.*

FDA Label Image

200 U/ml Ifu Figure P (Image 60)

Illustration showing a hand holding a pen-like injection device with instructions to count slowly from 1 to 6 while preparing or administering the injection. The image emphasizes timing during use of the injection device.*

FDA Label Image

200 U/ml Ifu Figure Q (Image 61)

An instructional illustration depicting how to insert or attach a component by pushing upward. The image shows a pen-type injector with an arrow pointing upward, indicating the direction to push or remove the part.*

FDA Label Image

200 U/ml Ifu Figure R (Image 62)

Instructional illustration showing two steps for using a NovoFine and NovoTwist device. The images demonstrate the removal of protective caps from the needle before insulin injection with Insulin Degludec 100 U/mL injection solution by A-S Medication Solutions.*

FDA Label Image

200 U/ml Ifu Figure S (Image 63)

Illustration showing the connection of a needle cap to a syringe or injection pen, indicating the proper attachment or removal direction with arrows.*

FDA Label Image

200 U/ml Ifu Figure T (Image 64)

An instructional illustration showing how to engage or attach a component of a medical injection device, likely a cap or cover being removed by hands. The image focuses on hand positioning and a directional arrow indicating the movement direction for proper handling.*

FDA Label Image

Label Image (Lbl500907176)

Insulin Degludec FlexTouch Injection 100 units/mL (U-100) solution in a prefilled pen. The packaging indicates each milliliter contains 100 units of insulin degludec. Storage instructions specify keeping the product at 36 to 46 degrees Fahrenheit, avoiding freezing. The box contains 5 prefilled 3 mL pens. Labeler is A-S Medication Solutions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.